Profusa, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $PFSA in the last 7 days.
No SEC Form 4 filings for $PFSA in the last 30 days.
See all $PFSA insider activity →Profusa, Inc. (PFSA) received ISO 13485:2016 certification from GMED, a step toward MDR certification and CE marking for its Lumee Oxygen Platform. The certification covers the design, development, and manufacture of the platform at its Berkeley facility. Profusa aims to begin manufacturing the platform and pursue commercial distribution in the EU, subject to regulatory approvals.
Profusa issued a $769K senior secured convertible note to Ascent Partners, raising $700K at 7% interest. The note matures by Oct. 15, 2027, or upon an option closing, and is convertible at $4.28 per share. The deal aims to enhance liquidity and provide conversion flexibility, according to the company.
Profusa, Inc. (PFSA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. As previously disclosed, the Company is party to a Securities Purchase Agreement, dated as of February 11, 2025 (as amended, the “Purchase Agreement”), by and among the Company, Ascent Partners Fund LLC, a Delaware limited lia
Recent PFSA coverage spans corporate actions, regulation and market movers.
The certification removes a key barrier to EU market entry and may lift the stock modestly.
The small convertible note adds liquidity but may dilute shareholders if converted.
The convertible note creates potential dilution and adds debt, likely pressuring the stock.
The amendment tightens conversion mechanics, potentially diluting existing shareholders if conversion occurs at lower prices.
Amendments tighten conversion terms, limiting dilution and improving noteholder protection.
AlphAI scores every news story that mentions PFSA with an AI model for sentiment and relevance, and aggregates insider trades from Profusa, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Profusa, Inc. (PFSA) received ISO 13485:2016 certification from GMED, a step toward MDR certification and CE marking for its Lumee Oxygen Platform. The certification covers the design, development, and manufacture of the platform at its Berkeley facility. Profusa aims to begin manufacturing the platform and pursue commercial distribution in the EU, subject to regulatory approvals.
2 min readProfusa issued a $769K senior secured convertible note to Ascent Partners, raising $700K at 7% interest. The note matures by Oct. 15, 2027, or upon an option closing, and is convertible at $4.28 per share. The deal aims to enhance liquidity and provide conversion flexibility, according to the company.
1 min readProfusa, Inc. (PFSA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. As previously disclosed, the Company is party to a Securities Purchase Agreement, dated as of February 11, 2025 (as amended, the “Purchase Agreement”), by and among the Company, Ascent Partners Fund LLC, a Delaware limited lia
2 min readProfusa amended two convertible notes with Ascent Partners Fund, setting a $0.338 floor price and VWAP-based conversion terms. The notes, maturing in April 2027, have principal amounts of $555,555.55 and $1,111,111.11. Share reserves are set at 150% of the floor price, and anti-dilution provisions were waived on other notes.
1 min readProfusa, Inc. (PFSA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. As previously disclosed, the Company is party to a Securities Purchase Agreement, dated as of February 11, 2025 (as amended, the “Purchase Agreement”), by and among the Company, Ascent Partners Fund LLC, a Delaware limited lia
2 min readBiotech stocks APUS, PFSA, GCTK, and ARCT saw notable moves. APUS surged 130% without specific news, plans Phase 3 trial for Apitox. PFSA up 49.14% after ISO 13485 certification progress. GCTK raised $3.1M via stock offering, up 25.62%. ARCT rose 6.77% on Phase 2 results and LUNAR 2.0 platform news. Q2 losses reported for APUS.
3 min readProfusa (PFSA) received a positive ISO 13485 decision from GMED, advancing its Lumee Oxygen Platform toward CE marking in the EU. The platform monitors tissue oxygen levels. Profusa expects ISO certification in early October but cautions on timing uncertainties. PFSA stock is up 86.82% in pre-market trading.
1 min readProfusa, Inc. (PFSA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On September 18, 2026, the Company held a Special Meeting of Stockholders (the “Meeting”), which was convened virtually at www.virtualshareholdermeeting.com/PFSA2026SM , pursuant to notice duly given. Definitive proxy
1 min readProfusa, Inc. (PFSA) raised $350,000 via a senior secured convertible note from Ascent Partners Fund. The note has a 7% interest rate, matures by September 16, 2027, and is convertible at $4.28 per share. Proceeds aim to bolster liquidity, with note repayment conditions tied to future fundraisings.
1 min readProfusa, Inc. (PFSA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Senior Secured Convertible Promissory Note On September 16, 2026, Profusa, Inc., a Delaware corporation (the “Company”), completed an additional closing under that certain Securities Purchase Agreement, dated as of February 11
1 min read
